Skip to Content
Merck

A5602

AMD3100 octahydrochloride hydrate

≥97% (NMR), solid, CXCR4 antagonist

Synonym(s):

1,1′-[1,4-Phenylenebis(methylene)]bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride, JM3100, Plerixafor, SID791

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C28H54N8 · 8HCl · xH2O
CAS Number:
155148-31-5
Molecular Weight:
794.47 (anhydrous basis)
MDL number:
MFCD29072959
UNSPSC Code:
51111800
PubChem Substance ID:
24724394
NACRES:
NA.77
Assay:
≥97% (NMR)
Form:
solid
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

AMD3100 octahydrochloride hydrate, ≥97% (NMR), solid

SMILES string

Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].Cl[H].[H]O[H].C1CNCCNCCCN(CCNC1)Cc2ccc(CN3CCCNCCNCCCNCC3)cc2

InChI

1S/C28H54N8.8ClH.H2O/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H;1H2

InChI key

GKFHDCZYJHUPEN-UHFFFAOYSA-N

assay

≥97% (NMR)

form

solid

storage condition

desiccated

solubility

H2O: ≥10 mg/mL, clear

originator

Sanofi Aventis

storage temp.

−20°C

Quality Level

100

Related Categories

Application

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist. AMD3100 has been used in a study to determine the blockade of CXCR4 in oral squamous cell carcinoma and inhibition of lymph node metastases.

Biochem/physiol Actions

AMD3100 is a highly specific chemokine receptor CXCR4 antagonist.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000534207
0000534207
0000479917
0000479917
0000428487

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniele Biasci et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(46), 28960-28970 (2020-11-01)
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer responses in murine and human pancreatic cancer. Here we elucidate the mechanism by which CXCR4 inhibition affects the
Kelli P A MacDonald et al.
Journal of immunology (Baltimore, Md. : 1950), 192(7), 3180-3189 (2014-03-04)
The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mobilized peripheral blood stem cells. G-CSF has diverse biological effects on a broad range of cells and IL-10 is a key regulator of many of these effects. Using
Andreas Lundqvist et al.
Journal of immunology (Baltimore, Md. : 1950), 191(12), 6241-6249 (2013-11-19)
Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter
Sapna Devi et al.
The Journal of experimental medicine, 210(11), 2321-2336 (2013-10-02)
Blood neutrophil homeostasis is essential for successful host defense against invading pathogens. Circulating neutrophil counts are positively regulated by CXCR2 signaling and negatively regulated by the CXCR4-CXCL12 axis. In particular, G-CSF, a known CXCR2 signaler, and plerixafor, a CXCR4 antagonist
Christine Feig et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(50), 20212-20217 (2013-11-28)
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. Despite finding that PDA-bearing mice had cancer cell-specific CD8(+) T cells, the mice, like human patients with PDA, did not
View All Related Papers

Related Content

Product Information Sheet - A5602

Product Information Sheet

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service